{"id":2527,"date":"2026-04-03T17:10:58","date_gmt":"2026-04-03T20:10:58","guid":{"rendered":"https:\/\/saudedaprostata.ufc.br\/?page_id=2527"},"modified":"2026-04-03T17:40:06","modified_gmt":"2026-04-03T20:40:06","slug":"pesquisas-em-2026","status":"publish","type":"page","link":"https:\/\/saudedaprostata.ufc.br\/?page_id=2527","title":{"rendered":"Pesquisas em 2025 e 2026"},"content":{"rendered":"\n

PUBLICA\u00c7\u00d5ES DE TRABALHOS DESENVOLVIDOS NOS PROGRAMAS DE P\u00d3S GRADUA\u00c7\u00c3O EM PATOLOGIA E PROGRAMA DE POS GRADUA\u00c7\u00c3O CI\u00caNCIAS M\u00c9DICO CIR\u00daRGICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE FEDERAL DO CEAR\u00c1<\/strong><\/p>\n\n\n\n

Desenvolvidos pelos alunos de doutorado e alunos bolsistas de Extens\u00e3o e de Inicia\u00e7\u00e3o cient\u00edfica do Curso Medicina da UFC<\/p>\n\n\n\n

Em 2026:<\/a><\/p>\n\n\n\n

Metilnitrosoureia na carcinog\u00eanese de bexiga: O que temos para aprender em uma revis\u00e3o narrativa<\/strong><\/h1>\n\n\n\n

Esmeraldo Cristino Nobre Traquino<\/a>; Concei\u00e7\u00e3o Aparecida Dornelas<\/a>; Jhonas Nathnael Menezes Ferreira<\/a>; Felipe Dias Gonsalves<\/a>; Esau Lima Brasilino de Freitas<\/a><\/h2>\n\n\n\n

http:\/\/dx.doi.org\/10.4322\/col.2026.002<\/a>Clin Onc Let, vol.6, n1, <\/a>p.1-10, 2026<\/p>\n\n\n\n

 PDF<\/a><\/p>\n\n\n\n

Resumo<\/h2>\n\n\n\n

INTRODU\u00c7\u00c3O: N-metil-N-nitrosoureia (MNU) um agente cancer\u00edgeno, atua diretamente no urot\u00e9lio para indu\u00e7\u00e3o de c\u00e2ncer experimental de bexiga e em outros \u00f3rg\u00e3os. O objetivo \u00e9 uma revis\u00e3o narrativa de diferentes protocolos de uso do N-metil-N-nitrosoureia na carcinog\u00eanese da bexiga em roedores. M\u00c9TODO: As bases pesquisadas foram Scientific Eletronic Library Online; PUBMED e GOOGLE ACAD\u00caMICO, foram selecionados 22 artigos publicados nos intervalos dos anos 1972 a 2026. A revis\u00e3o foi mediada pelos descritores, metilnitrosoureia, c\u00e2ncer experimental de bexiga, ratos e camundongos. RESULTADOS: O N-metil-N-nitrosoureia n\u00e3o \u00e9 um carcin\u00f3geno espec\u00edfico para bexiga, e desta forma precisa ser inoculado na via vesical. O fracionamento das doses de modo semanal mostra uma tend\u00eancia a uma melhor indu\u00e7\u00e3o de c\u00e2ncer de bexiga, evidenciado. CONCLUS\u00c3O: As vantagens gerais s\u00e3o de N-metil-N-nitrosoureia ser um carcin\u00f3geno que tem menor custo e que pode produzir tumores vesicais em ratos Wistar em menos tempo que os demais carcin\u00f3genos vesicais dispon\u00edveis e maior desvantagem em rela\u00e7\u00e3o a dose \u00e9 a necessidade de longos per\u00edodos de observa\u00e7\u00e3o para desenvolvimento tumoral. A pielonefrite e a perfura\u00e7\u00e3o uretral\/vesical constituem as principais complica\u00e7\u00f5es pela via de inocula\u00e7\u00e3o intravesical.<\/p>\n\n\n\n

Em 2025 <\/strong><\/h2>\n\n\n\n

Investigation of androgen receptor expression in urothelial carcinoma of the bladder<\/strong><\/h1>\n\n\n\n

https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12752205<\/a><\/p>\n\n\n\n

Andr\u00e9 Lu\u00eds Nunes Avelino<\/a> 1,<\/sup>\u2709<\/sup>, Felipe Dias Gon\u00e7alves<\/a> 2<\/sup>, Jhonas Nathanael Menezes Ferreira<\/a> 3<\/sup>, Gislane Rocha Vasconcelos<\/a> 4<\/sup>, Concei\u00e7\u00e3o Aparecida Dornelas<\/a> 5<\/sup><\/p>\n\n\n\n

PMCID: PMC12752205  PMID: 41430666<\/a><\/p>\n\n\n\n

<\/a>Abstract<\/h2>\n\n\n\n

Background<\/h3>\n\n\n\n

Studies have demonstrated the importance of the androgen receptor (AR) in the development of bladder cancer and have proposed it as a potential biomarker or therapeutic hypothesis. However, the relationship between AR expression and both clinical features of patients and intrinsic tumor characteristics remains uncertain.<\/p>\n\n\n\n

Aims<\/h3>\n\n\n\n

To evaluate the association between AR immunohistochemical expression and clinical as well as pathological characteristics of bladder cancer.<\/p>\n\n\n\n

Methods<\/h3>\n\n\n\n

We conducted a retrospective cohort including patients diagnosed with bladder cancer through transurethral resection of the bladder (TURB) between 2016 and 2021. For each case, AR immunoexpression was tested and analyzed in relation to sex, age, smoking history, number of tumor foci, tumor size, vascular invasion, histological grade, carcinoma in situ, and pathological stage.<\/p>\n\n\n\n

Results<\/h3>\n\n\n\n

Low AR expression was observed in 97.5% of cases, while high expression was identified in 1.4% and indeterminate cases accounted for 1.1% of the cohort. AR immunoexpression was not related to clinical or pathological variables.<\/p>\n\n\n\n

Conclusion<\/h3>\n\n\n\n

No significant associations were identified between AR expression and clinical or pathological variables, suggesting that its potential role as a biomarker in bladder cancer warrants further investigation.<\/p>\n\n\n\n

Em 2025 <\/strong><\/h3>\n\n\n\n

Androgen Receptor Expression in Bladder Cancer: Prognostic Implications<\/strong><\/h1>\n\n\n\n

Andr\u00e9 Avelino<\/strong>
Fellow PhD Degree, Universidade Federal do Cear\u00e1, Brazil<\/p>\n\n\n\n

Felipe Gon\u00e7alves<\/strong>
Graduate Student, Universidade Federal do Cear\u00e1, Brazil<\/p>\n\n\n\n

Jhonas Ferreira<\/strong>
Graduate Student, Universidade Federal do Cear\u00e1, Brazil<\/p>\n\n\n\n

MD, Gislane Rocha Vasconcelo<\/strong>
Pathologist, Nordd Laborat\u00f3rio de Patologia, Brazil<\/p>\n\n\n\n

Ph. D, Concei\u00e7\u00e3o Dornelas<\/strong>
Associate Professor, Universidade Federal do Cear\u00e1, Brazil<\/p>\n\n\n\n

\n
Article Detail<\/a><\/blockquote>